US Stock MarketDetailed Quotes
SLNCF SILENCE THERAPEUTICS PLC
- 6.650
- +0.095+1.45%
15min DelayClose Sep 13 16:00 ET
933.62MMarket Cap-15501P/E (TTM)
6.650High6.650Low167Volume6.650Open6.555Pre Close1.11KTurnover0.00%Turnover RatioLossP/E (Static)140.39MShares14.75052wk High6.36P/B591.81MFloat Cap0.60052wk Low--Dividend TTM88.99MShs Float46.500Historical High--Div YieldTTM0.00%Amplitude0.600Historical Low6.650Avg Price1Lot Size
About SILENCE THERAPEUTICS PLC Company
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
Company Profile
SymbolSLNCF
Company NameSILENCE THERAPEUTICS PLC
Founded1994
CEOMr. Craig A. Tooman
MarketPink Market
Employees109
Fiscal Year Ends12-31
Address72 Hammersmith Road
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW14 8TH
Phone44-20-3457-6900
Company Executives
- Name
- Position
- Salary
- Craig A. Tooman
- President, Chief Executive Officer and Director
- 7.30M
- Rhonda L. Hellums
- Chief Financial Officer
- 2.50M
- Iain Gladstone Ross
- Non-Executive Chairman of the Board
- 402.00K
- James Lawrence Ede-Golightly
- Independent Director
- 182.00K
- David Jakob Lemus
- Independent Director
- 184.00K
- Dr. Michael Harvey Davidson, M.D.
- Independent Director
- 178.00K
- Alistair William Gray
- Senior Independent Director
- 193.00K
- Dr. Steven Joseph Romano, M.D.
- Head of Research and Development
- 1.73M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data